



BEST AVAILABLE COPY

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Ashok TEHIM et al.

Serial No.: 10/669,645

Group Art Unit: 1614

Filed: September 25, 2003

Examiner: Unassigned

For: INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND
PREPARATION AND USES THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

- Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:
 - within three months of the filing date of a national application other than a CPA under § 1.53(d);
 - within three months of the actual filing date of the national phase of a PCT application; OR
 - before the mailing of a first substantive office action (including after filing of an RCE).
- Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:
 - a final rejection under 37 C.F.R. 1.113;
 - termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P. § 609(B)(2); OR
 - a notice of allowance under 37 C.F.R. § 1.311; and

is accompanied by:

- the statement as specified in 37 C.F.R. § 1.97(e) set out below, OR
- a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).

Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:

- a final action under 37 C.F.R. § 1.113;
- termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P. § 609(B)(2); OR
- a notice of allowance under 37 C.F.R. § 1.311;

AND is filed on or before payment of the issue fee; AND is accompanied by:

- the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).

Statements Under 37 C.F.R. 1.97(e)

- Each item of information contained in this information disclosure statement was a first cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.

Cited Materials

- Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No. _____, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).
- Copies of materials listed and are attached (except for US references) were cited in an international search report dated _____.

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



Brion P. Heaney, Reg. No. 32,542
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MEMORY-33

Date: June 16, 2004

BPH/rrt



Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

3

Complete if Known

Application Number	10/669,645
Filing Date	September 25, 2003
First Named Inventor	Ashok Tehim
Group Art Unit	1614
Examiner Name	Unassigned

Attorney Docket Number

MEMORY-33

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
		4,789,673		Donatsch et al.	12/6/1988
		4,798,829		King et al.	1/17/1989
		4,845,092		Sanger et al.	7/4/1989
		4,886,808		King	12/12/1989
		4,910,193		Buchheit	3/20/1990
		4,937,247		King	6/26/1990
		4,942,160		Sanger et al.	7/17/1990
		4,975,436		Tyers	12/4/1990
		4,985,424		van Wijngaarden et al.	1/15/1991
		5,034,398		King	7/23/1991
		5,063,231		Sanger et al.	11/5/1991
		5,098,909		Williams	3/24/1992
		5,192,770		Clark et al.	3/9/1993
		5,204,356		Tyers	4/20/1993
		5,272,154		Dixon et al.	12/21/1993
		5,273,972		Jagdmann et al.	12/28/1993
		5,543,426		Dixon et al.	8/6/1996
		5,446,050		Rosen	8/29/1995
		5,561,149		Azria et al.	10/1/1996
		5,641,802		Arcamone et al.	6/24/1997
		5,773,436		Muller et al.	6/30/1998
		5,985,866		Muller et al.	11/16/1999
		6,492,385		Myers et al.	12/10/2002
		6,500,840		Myers et al.	12/31/2002
		6,599,916		Myers et al.	7/29/2003
		6,624,173		Crooks et al.	9/23/2003
		US 2003/0073707		Walker et al.	4/17/2003
		US 2004/0002513		Mazurov et al.	1/1/2004

Examiner Signature

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Copies of the materials listed are attached (except US references).

Non-English Language References

An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).

A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:

X = document of particular relevance when it is taken alone
Y = document of particular relevance when it is combined with another such document
A = document defining the general state of the art
O = non-written disclosure
P = intercalated document
T = document cited to understand the theory or principle underlying the invention
E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
D = cited in the application
L = cited for another reason
& = publication of member of same patent family

Translation of other relevant information on foreign search report

Other Information

Payment of Fees Due (If Any):

A check for \$_____ covering the fee identified above is attached.

Please charge to Deposit Account No. 13-3402 \$_____ for the fee identified above.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/669,645
Filing Date	September 25, 2003
First Named Inventor	Ashok Tehim
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-33

Sheet 2 of 3

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		JP	2002-30084			1/29/2002		
		GB	2 125 398			3/7/1984		
		EP	0 200 444			11/5/1986		
		EP	0 498 466			8/12/1992		
		EP	1 235 826			9/4/2002		
		WO	92/12149			7/23/1992		
		WO	02/085901			10/31/2002		
		WO	02/100833			12/19/2002		
		WO	02/100858			12/19/2002		
		WO	02/17358			2/28/2002		
		WO	03/022856			3/20/2003		
		WO	03/042210			5/22/2003		
		WO	03/072578			9/4/2003		
		WO	03/078431			9/25/2003		
		WO	03/094830			11/20/2003		
		WO	03/101987			11/12/2003		
		GB	2 145 416			3/27/1985		
		FR	2 548 666			1/11/1985		
		EP	0 214 772			3/18/1987		
		EP	1 079 828			3/7/2001		
		WO	84/00166			1/19/1984		
		WO	85/01048			3/14/1985		

Examiner
Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/669,645
Filing Date	September 25, 2003
First Named Inventor	Ashok Tehim
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-33

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		S.M. Evans et al., "Probing the 5-HT ₃ Receptor Site Using Novel Indole-3-Glyoxylic Acid Derivatives", Med. Chem. Res. (1993), 3:386-406	
		D. Flammia, "Lobeline: Structure-Affinity Investigation of Nicotinic Acetylcholinergic Receptor Binding", J. Med. Chem. (1999), 42:3726-2731	
		R. Azuma et al. "Metabolism and Disposition of GTS-21, A Novel Drug for Alzheimer's Disease", Xenobiotica (1999), Vol. 29, No. 7, pgs. 747-762	
		K. E. Stevens. Et al., "Selective α ₇ -nicotinic agonists normalize inhibition of auditory response in DBA mice", Psychopharmacology (1998), 136:320-327	
		R. Azuma et al., "The effect of repeat administration of GTS-21 on mixed-function oxidase activities in rat", Elsevier Science Ireland Ltd., Toxicology Letters 110 (1999) pgs. 137-144	
		M. Decker, et al., "Neuronal Nicotinic Acetylcholine Receptors: Novel Targets for CNS Therapeutics", pgs. 1-14	
		M. W. Holladay et al., "Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery", Journal of Medicinal Chemistry, Vol. 40, No. 26, (1997), pgs. 4169-4194.	

Examiner
Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.